Mylan believes that US Food and Drug Administration (FDA) approval of its Wixela Inhub generic alternative to GlaxoSmithKline’sAdvair Diskus (fluticasone/salmeterol) respiratory blockbuster is “imminent”. “Mylan confirms it has not received any new information request or complete response letter (CRL) from the FDA,” the company said in a statement issued on 22 October.
Mylan believes that US Food and Drug Administration (FDA) approval of its Wixela Inhub generic alternative to GlaxoSmithKline’sAdvair Diskus (fluticasone/salmeterol) respiratory blockbuster is “imminent”. “Mylan confirms it has not received any new information request or complete response letter (CRL) from the FDA,” the company said in a statement issued on 22 October.
In August, Mylan had indicated that it had an FDA action date for Wixela Inhub in “mid-October”, having responded to...
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
